Laboratory Fraud Cases: The Order, the Payment and the People Behind Them

Laboratory fraud cases expose how unnecessary tests, bought referrals and false bills turn a specimen into government money. A laboratory can expand the order, pay the practice sending the patient, or charge for work its own records cannot explain. The cases below follow those decisions through settlements, admissions and court judgments. If you work in laboratory sales, billing, testing or a referring practice, the arrangement behind the payment may be more familiar than the company in the headline.

What Schemes Do Laboratory Fraud Cases Reveal?

Millennium Health, Health Diagnostic Laboratory and Labcorp illustrate different kinds of laboratory whistleblower cases: unnecessary testing, payments for referrals and repeated charges for one test.

Custom Profiles Turn Patient Decisions Into Repeat Orders

Millennium Health’s 2015 settlement resolved allegations of medically unnecessary urine drug and genetic testing and free items supplied to referring physicians. The urine-testing portion was $227 million. The government alleged that Millennium supplied free test cups to physicians who agreed to send it testing. The cup helped secure the specimen, and the specimen brought the laboratory the testing business.

Precision Toxicology, operating as Precision Diagnostics, agreed to a $27 million settlement in 2024. The government alleged that its custom profiles operated as standing orders, producing excessive urine drug tests without an assessment of each patient’s needs. The alleged conduct ran from 2013 through 2022.

Genotox Laboratories went further in its 2023 civil settlement: it admitted offering custom profiles that preselected tests for all or nearly all of a provider’s patients, generally in the highest reimbursement categories. Its settlement was at least $5.9 million. The form had made the recurring decision before the next patient’s specimen arrived.

That distinction matters in the trade. The treating clinician orders the test, while the laboratory performs and bills it. The Department of Health and Human Services Office of Inspector General’s laboratory compliance guidance places the medical-necessity decision with the clinician. A laboratory’s order form can quietly move that decision into its own sales process.

The problem was visible long before today’s toxicology cases. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described monitoring standing orders for continued validity, documenting the need for each ordered test and explaining how profiles would be billed. The order form, the test-use data and the physician’s understanding were already the places to look.

What Happened to the Health Diagnostic Laboratory Scandal?

Health Diagnostic Laboratory agreed to pay $47 million in 2015 to settle allegations of referral kickbacks and unnecessary testing. In the same Justice Department announcement, Singulex agreed to a separate $1.5 million settlement. The government alleged that the laboratories paid processing and handling fees of $10 to $17 per referral and routinely waived patient copayments and deductibles.

The later trial concerned the people running and selling the arrangement. A jury found HDL’s former chief executive and the people who marketed its tests through BlueWave liable for causing false claims. The court entered a civil judgment of $114,148,662 against those individuals in 2018, according to the U.S. Attorney’s announcement.

The fee’s label made the payment sound like compensation for handling blood. Its connection to each referral explains why the payment records matter alongside the laboratory results. Under the alleged arrangement, taxpayers financed unnecessary testing while the referring practice collected a fee for sending the business.

RDx Bioscience’s 2024 settlement concerned another set of labels. The government alleged that marketers paid providers consulting or medical-director fees to induce test orders, and that other referral payments appeared as investment returns. The work performed and the referral arrangement explain what those payments bought.

Genetic Testing Begins at the Recruiting End

Genetic-testing cases often begin with the marketer who obtains the beneficiary’s information and the clinician’s signature. In the criminal trial involving Axis Professional Labs and Kingdom Health Laboratory, evidence showed marketers using telemarketing and pressuring patients’ physicians to approve tests. Nonmedical personnel had already decided that the patients qualified. The laboratory owner was convicted in 2026.

The operator in the criminal case involving Express Diagnostics, BioConfirm Laboratory USA, Tox Management and Tri-State Toxicology pleaded guilty. The Justice Department’s account of that case describes marketers obtaining DNA samples through health fairs, door-to-door solicitation and telemarketing. In exchange for kickbacks, the marketers obtained fraudulent requisitions from providers who had not treated or consulted with the beneficiaries. Those providers did not use the results in treatment.

For someone inside that chain, the sales script, the order and the payment to the recruiter describe different parts of the same transaction. The clinical paperwork comes last, after the business has already acquired the patient.

The Bill Can Outgrow the Test

Unperformed testing and repeated billing create another mismatch. In the whistleblower complaint against Princeton Pathology Services, a physician alleged that his own emergency visit generated charges for tests his treating physician had not ordered and that he had not undergone. The allegation started with the patient’s bill and what happened in the examination room. Princeton agreed to a $2.4 million settlement in 2021.

A former Labcorp employee’s complaint described a different discrepancy at Walter Reed: Labcorp allegedly charged for each family member’s specimen when its outside testing provider charged once for the child’s or fetus’s report. The complaint quoted an internal email:

The specimen count and the purchased service were different things. The allegation depended on comparing the supplier’s charge with the government’s bill. Labcorp’s settlement of that case was $2.1 million in 2023.

An older variation added work to the panel and then billed it separately. Meris Laboratories’ 1997 settlement resolved allegations that it added unnecessary cholesterol and serum iron tests physicians had not specifically ordered. Unbundling works in the other direction: a laboratory bills a panel’s components separately at a higher total price.

Collection Trips and Unpaid Hospital Bills

Labcorp’s 1997 mileage settlement concerned allegedly overstated car mileage for phlebotomists visiting homebound and nursing home patients. The disputed claim concerned the trip to collect the specimen.

Genomic Health’s 2023 settlement concerned hospital invoices it allegedly failed to send on time for laboratory services under Medicare’s 14-day rule. It then wrote off the unpaid fees. The alleged inducement to the hospital was a laboratory bill it did not have to pay.

Inaccurate Results Can Start With the Test Kit

Nichols Institute Diagnostics admitted in its guilty plea that it knowingly marketed a misbranded parathyroid hormone assay. The Justice Department’s account described a product marketed as comparable to another assay even though the company knew its results were not consistently equivalent.

The federal civil settlement involving Quest Diagnostics and Nichols was $262 million in 2009. The civil allegations reached claims submitted by laboratories and medical providers using the kits, including claims for unnecessary treatment. Here, knowledge about the instrument and its performance mattered upstream from the billing department.

Repeat Laboratory Fraud Settlements Can Concern Different Conduct

Repeat laboratory fraud settlements have addressed different conduct at LabTox, Inform Diagnostics and Singulex, from testing methods to referral payments and diagnosis codes.

LabTox’s 2019 settlement concerned allegations that it billed for high-complexity urine testing while using a low-complexity method, and billed specimen validity testing. A three-year integrity agreement accompanied that resolution. In his guilty plea in the later criminal case, its owner admitted billing Medicare and Kentucky Medicaid for court-ordered tests used in judicial proceedings that were not medically necessary. The Justice Department announced civil judgments in 2024. The government’s complaint in the case that led to those 2024 civil judgments included a 2018 order form and a standing-order letter attached to a November 6, 2019 email, both predating the announcement of LabTox’s separate settlement on November 19, 2019.

Inform Diagnostics, formerly Miraca Life Sciences, had three resolutions. Its 2019 settlement concerned alleged electronic-health-record subsidies and free or discounted technology consulting for referring physicians. Its 2022 settlement concerned routine additional tests the government alleged were medically unnecessary. A further settlement followed a self-disclosure in 2024.

Singulex’s later settlement in 2018 concerned allegations that it pressured providers to select diagnosis codes without regard to the patient’s condition or added codes without the provider’s knowledge or consent. The earlier case concerned referral payments. One company name can conceal very different decisions inside the business.

Precision’s five-year corporate integrity agreement shows what scrutiny after settlement can reach. Its required claims reviews cover registrations, requisitions, order forms and test results. Sales leadership is among the officials required to certify compliance. The review reaches back from the paid claim to the people who generated the order.

Laboratory Acquisitions and Fraud Settlements Reach Earlier Billing

Quest and Labcorp have resolved laboratory fraud allegations involving businesses they acquired.

Quest acquired Nichols Institute in 1994. The earlier Nichols case in the federal laboratory fraud investigation concerned conduct beginning in 1989 and ending shortly after that acquisition. Quest acquired Berkeley HeartLab through Celera in 2011 and paid $6 million in a 2017 settlement over Berkeley’s alleged referral kickbacks and unnecessary testing.

National Health Laboratories acquired Allied Clinical Laboratories in June 1994. Its merger with Roche Biomedical Laboratories created Labcorp in April 1995. Labcorp resolved the combined panel-testing allegations as successor to those businesses in 1996.

Labcorp acquired Dianon Systems in January 2003. Dianon’s separate settlements concerned allegedly unperformed second-opinion consultations and unnecessary urine cytology DNA analysis, followed by a later case involving a fixed battery of flow cytometry tests on every sample.

Laboratory Fraud Statistics Show the Money Behind the Orders

LabSolutions billed Medicare more than $463 million and received more than $187 million, according to the Justice Department’s account of the criminal case against its owner, who was convicted at trial. The owner knew telemedicine doctors signed orders without treating the beneficiaries and often without speaking to them.

Millennium’s whistleblowers were awarded $30.35 million from the urine-testing settlement proceeds.

Administrative cases can reveal a narrower billing practice. Florida Family Laboratories agreed to a 2014 settlement with the HHS Office of Inspector General over allegations that it used an inappropriate code to bypass claim edits and bill more high-complexity urine-test units than Medicare allowed.

Is the Department of Justice Cracking Down on Lab Fraud?

The Department of Justice resolved allegations in 2024 that Precision Toxicology used custom profiles to generate excessive urine testing without assessing each patient’s needs. In the 2026 criminal trial involving Axis Professional Labs and Kingdom Health Laboratory, evidence showed marketers pressuring physicians to approve genetic tests for patients already selected by nonmedical personnel.

The People Who Can Connect the Records

Laboratory whistleblowers have included sales representatives, billing employees, clinicians, quality-control staff and competitors. A sales employee can explain the referral offer. Someone at the bench can explain the test that actually ran. Billing staff can explain why a specimen became several charges. That knowledge gives the paperwork its meaning.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We work with people who recognize these arrangements to assess the laboratory’s decisions, the claims they produced and the strongest case their knowledge can support.

Recognize the Arrangement Inside Your Laboratory?

If you know who expanded the orders, approved the referral payments or kept the billing practice in place, speak with our laboratory fraud whistleblower experts. We build the case strategy with you and bring in laboratory fraud whistleblower lawyers who understand the testing, the reimbursement and the people behind the claims. We stay beside you throughout the whistleblower process.